Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study.

PubWeight™: 0.90‹?›

🔗 View Article (PMC 4095575)

Published in Crit Care on June 10, 2014

Authors

Paula Peyrani, Timothy L Wiemken, Robert Kelley, Marcus J Zervos, Daniel H Kett, Thomas M File, Gary E Stein, Kimbal D Ford, Ernesto G Scerpella, Verna Welch, Julio A Ramirez, IMPACT-HAP Study Group

Articles cited by this

What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA (1998) 26.79

Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med (2005) 23.85

NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol (2008) 13.49

Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis (2012) 7.97

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 5.64

Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis (2011) 5.42

Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med (2005) 2.61

Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med (2011) 2.39

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med (2004) 2.30

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis (2001) 2.19

Calculating the "number needed to be exposed" with adjustment for confounding variables in epidemiological studies. J Clin Epidemiol (2002) 1.99

Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest (2010) 1.90

Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies. Crit Care Med (2011) 1.82

Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol (2012) 1.82

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther (2003) 1.33

Attributable mortality of ventilator-associated pneumonia. Curr Opin Crit Care (2011) 1.02

Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study. Crit Care (2011) 0.95

Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Ann Pharmacother (2012) 0.86

Articles by these authors

Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91

Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2009) 6.52

Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88

Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis (2011) 5.42

Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis (2005) 5.24

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis (2003) 5.21

Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis (2011) 3.08

Thrombocytopenia associated with linezolid therapy. Clin Infect Dis (2002) 2.93

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis (2003) 2.84

Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia. Eur Respir J (2013) 2.69

SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis (2008) 2.56

Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. JAMA (2013) 2.55

Relationship of baseline glucose homeostasis to hyperglycemia during medical critical illness. Chest (2004) 2.50

IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis (2012) 2.43

Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest (2009) 2.34

Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest (2010) 2.25

A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med (2007) 2.08

Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest (2010) 1.90

Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. J Infect Dis (2013) 1.86

A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother (2011) 1.68

Application of molecular techniques to the study of hospital infection. Clin Microbiol Rev (2006) 1.57

Eighteen years of experience with Acinetobacter baumannii in a tertiary care hospital. Crit Care Med (2013) 1.54

Multiplex PCR for detection of aminoglycoside resistance genes in enterococci. Antimicrob Agents Chemother (2003) 1.51

Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J Clin Microbiol (2008) 1.49

Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis (2008) 1.49

Legionnaires disease with bacteremic coinfection. Clin Infect Dis (2002) 1.46

Optimizing therapy for community-acquired pneumonia with the goal of rapid resolution of illness. Clin Infect Dis (2005) 1.43

Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotype. Antimicrob Agents Chemother (2003) 1.42

Pertinacious habit on a rehabilitation unit: repetitive finger licking while paging through the clinical chart. Am J Phys Med Rehabil (2004) 1.41

Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med (2009) 1.40

Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis (2012) 1.38

Association between the presence of enterococcal virulence factors gelatinase, hemolysin, and enterococcal surface protein and mortality among patients with bacteremia due to Enterococcus faecalis. Clin Infect Dis (2002) 1.33

Human and swine hosts share vancomycin-resistant Enterococcus faecium CC17 and CC5 and Enterococcus faecalis CC2 clonal clusters harboring Tn1546 on indistinguishable plasmids. J Clin Microbiol (2011) 1.31

Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med (2005) 1.27

Dissemination of an Enterococcus Inc18-Like vanA plasmid associated with vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2010) 1.26

daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother (2007) 1.25

Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis (2011) 1.25

Differences in self-management behaviors and use of preventive services among diabetes management enrollees by race and ethnicity. Dis Manag (2006) 1.23

Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis (2003) 1.19

Comparative evaluation of epidemiology and outcomes of methicillin-resistant Staphylococcus aureus (MRSA) USA300 infections causing community- and healthcare-associated infections. Int J Antimicrob Agents (2009) 1.19

Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database. Clin Ther (2012) 1.17

Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis (2012) 1.13

Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver disease in HIV-infected patients. Alcohol Res Health (2010) 1.13

Role of environmental surveillance in determining the risk of hospital-acquired legionellosis: a national surveillance study with clinical correlations. Infect Control Hosp Epidemiol (2007) 1.12

Telavancin: a novel lipoglycopeptide. Clin Infect Dis (2009) 1.11

Proteomic analysis of differentially expressed Chlamydia pneumoniae genes during persistent infection of HEp-2 cells. Infect Immun (2002) 1.10

Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. Int J Infect Dis (2012) 1.05

Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton-Valentine leukocidin gene. Clin Infect Dis (2011) 1.04

Global changes in the epidemiology of community-acquired pneumonia. Semin Respir Crit Care Med (2012) 1.03

Analysis of pathogen and host factors related to clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2012) 1.03

Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest (2003) 1.02

Evaluation of the knowledge-sharing social network of hospital-based infection preventionists in Kentucky. Am J Infect Control (2011) 0.99

Epidemiology of antimicrobial resistance in enterococci of animal origin. J Antimicrob Chemother (2004) 0.96

USA600 (ST45) methicillin-resistant Staphylococcus aureus bloodstream infections in urban Detroit. J Clin Microbiol (2010) 0.96

Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med (2013) 0.96

Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics. J Am Podiatr Med Assoc (2010) 0.96

Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study. Crit Care (2011) 0.95

Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis. J Antimicrob Chemother (2004) 0.95

Evidence for persistent Chlamydia pneumoniae infection of human coronary atheromas. Atherosclerosis (2007) 0.95